Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.58 |
| ▸ | HTRA2 | O43464 | 8/20 | 0.56 |
| ▸ | HTRA1 | Q92743 | 8/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401348 | 0.95 | FOLH1 (0.59) | ALBHTRA2HTRA1FOLH1ESR1 | |
| SCHEMBL14524697 | 0.95 | FOLH1 (0.59) | ALBHTRA2HTRA1FOLH1ESR1 | |
| SCHEMBL23291875 | 0.94 | FOLH1 (0.54) | ALBHTRA2HTRA1FOLH1ESR1 | |
| SCHEMBL15501043 | 0.90 | ALB (0.50) | ALBHTRA2HTRA1FOLH1ESR1 | |
| SCHEMBL4401282 | 0.89 | FOLH1 (0.60) | ALBFOLH1ESR1SLC5A2 | |
| SCHEMBL15501046 | 0.88 | FOLH1 (0.59) | ALBHTRA2HTRA1FOLH1ESR1 | |
| SCHEMBL9965269 | 0.85 | FOLH1 (0.52) | ALBHTRA2HTRA1FOLH1ESR1 | |
| SCHEMBL12675193 | 0.85 | ALB (0.58) | ALBHTRA2HTRA1FOLH1ESR1 | |
| SCHEMBL12040501 | 0.84 | ALB (0.57) | ALBHTRA2HTRA1FOLH1 | |
| SCHEMBL25673963 | 0.83 | ALB (0.60) | ALBHTRA2HTRA1FOLH1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028424-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190218592-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | PROMEGA CORPORATION | 2019-07-18 | — | — | US | disclosed |
| US-10240184-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190085305-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2019-03-21 | — | — | US | disclosed |
| US-20170097356-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-04-06 | — | — | US | disclosed |
| US-20170097356-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-04-06 | — | — | US | disclosed |
| US-20170088877-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-03-30 | — | — | US | disclosed |
| US-20170088877-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-03-30 | — | — | US | disclosed |
| US-9540402-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540402-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-7429472-B2 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION | 2008-09-30 | — | — | US | disclosed |
| US-7429472-B2 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION | 2008-09-30 | — | — | US | disclosed |
| US-7425436-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425436-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080026407-A1 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION | 2008-01-31 | — | — | US | disclosed |
| US-20080026407-A1 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION | 2008-01-31 | — | — | US | disclosed |
| US-7238842-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238842-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088877-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | GGT1, HDHD5, DNPH1 | ALB 3842/4885HTRA2 3649/4885HTRA1 2545/4885 |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | WASF2, NOTUM, YIPF5 | ALB 4212/4885HTRA2 3370/4885HTRA1 2119/4885 |
| US-20170097356-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | WASF2, NOTUM, YIPF5 | ALB 4212/4885HTRA2 3370/4885HTRA1 2119/4885 |
| US-20190085305-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | HDHD5, DDT, DDAH1 | ALB 1166/4885HTRA2 4051/4885HTRA1 2574/4885 |
| US-20190218592-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | GGT1, HDHD5, DNPH1 | ALB 3842/4885HTRA2 3649/4885HTRA1 2545/4885 |
| US-11028424-B2 | Covalent tethering of functional groups to proteins | GGT1, HDHD5, DNPH1 | ALB 3842/4885HTRA2 3649/4885HTRA1 2545/4885 |
| US-20080026407-A1 | Covalent tethering of functional groups to proteins | GGT1, HDHD5, DNPH1 | ALB 3842/4885HTRA2 3649/4885HTRA1 2545/4885 |
| US-10240184-B2 | Covalent tethering of functional groups to proteins | GGT1, HDHD5, DNPH1 | ALB 3842/4885HTRA2 3649/4885HTRA1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.